~~<i id='7D8F832B35'><strike id='7D8F832B35'><tt id='7D8F832B35'><pre id='7D8F832B35'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

explore

author：Wikipedia 2025-09-28 00:52:45 - browse：13

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Travis Kelce and the trap of celebrity vaccine endorsements

focus

Wikipedia

explore

knowledge

AdobeIrecentlystartedapatientwithmetastatictriple-positivebreastcancerpatientonatargetedtherapyregim

WSS

A Q&A with Aletha Maybank, AMA’s chief health equity officer

RSV vaccines may be linked to small increased risk of developing GBS

Clinical trials giant ICON acquires HumanFirst

How to convince healthy people to buy insurance

What is microchimerism and how does it affect maternal health?

How to fix the rural physician shortage in the U.S.

leisure time

explore

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Change Healthcare cyberattack outage could last weeks

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Kenai launches with $82 million for Parkinson’s stem cell therapy

What does generative AI mean for health care? We asked experts

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Moonlake's readout produced a cash windfall. Risks remain

Congress gives doctors Medicare pay bump

Moonlake's readout produced a cash windfall. Risks remain

Inari Medical to buy amputation prevention company LimFlow

focus

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

International team creates first chimeric human

Gene therapy’s promise and the high cost of hope

Why getting cancer drugs just got harder for rural patients

Pfizer highlights cancer drugs it thinks could reignite investor interest

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Wikipedia

explore

explore

knowledge